白细胞介素-1 受体拮抗剂与气道高反应性关系的研究

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (7): 759-762.

白细胞介素-1 受体拮抗剂与气道高反应性关系的研究

陈雪芹, 曹霞, 杨炯, 曹作炎

武汉大学人民医院呼吸内科, 武汉430060, 湖北

收稿日期:2004-05-13 修回日期:2004-06-04 出版日期:2004-07-26 发布日期:2020-11-20
通讯作者: 杨炯,男,教授,博士生导师,主要从事哮喘发生机制等研究。
作者简介:陈雪芹,女,博士生,主要从事哮喘的发病机制的研究。 E-mail:fish7062@public.wh.hb.cn

Research on relationship between interleukin-1 receptor antagonist and airway hyperresponsiveness

CHEN Xue-Qin, ZAO Xia, YANG Jiong, CAO Zuo-Yan

Department of Anapnea, Renming Hospital, Wuhan University, Wuhan 430060, Hubei, China

Received:2004-05-13 Revised:2004-06-04 Online:2004-07-26 Published:2020-11-20

摘要/Abstract

摘要： 目的: 探讨白细胞介素-1 受体拮抗剂(IL-1ra)与哮喘的气道高反应性(AHR)的关系。方法: 正常豚鼠,先腹腔注射卵清蛋白(OA)致敏而后雾化吸入OA激发豚鼠哮喘(哮喘组),激发前30min静脉注射IL-1ra 1mg·kg^-1(哮喘+IL-1ra 组),测定豚鼠的气道反应性(组胺的PC20值),并收集支气管肺泡灌洗液(BALF)进行细胞总数计数及分类记数。结果: 哮喘+IL-1ra 组PC₂₀ 值与对照组无显著性差异(P>0.05),显著高于哮喘组(P<0.01);BALF 中的中性粒细胞(NES)的百分比显著低于哮喘组(P<0.01)。所有豚鼠均存在-IgPC20值与BALF中的NES的百分比呈正相关(r=0.95,P<0.001)。结论: IL-1ra能降低AHR,其机制可能与IL-1ra减少NES的浸润有关。

关键词: 白细胞介素-1受体拮抗剂, 哮喘, 气道高反应性, 中性粒细胞

Abstract: AIM: To explore the relationship between interleukin-1receptor antagonist (IL-1ra) and airway hyperresponsiveness (AHR) of asthma.METHODS: The airway responsiveness to inhaled histamine as PC20 was evaluated among the normal guinea pigs, and sensitized with ovalbumine (OA) and challenged 14 days later (athma group), and injected IL-lra 1 mg·kg^-1 intravenously 30 minutes before challenged (asthma plus IL-lra group).The numbers of different cells was counted and classified in bronchoalveolar lavage fluid (BALF).RESULTS: The PC20 of the asthma plus IL-1ra group was higher than that of asthma group (P<0.01), and the percentage of the neutrophils (NES) in BALF of the asthma plus IL-1ra group was lower than that of the asthma group (P<0.01).There was a significant correlation between -IgPC₂₀ and the percentage of the NES in BALF in all animals(r=0.68,P<0.001).CONCLSION: IL-1ra can attenuate airway hyperresponsiveness, possibly by decreasing the airway infiltration of neutrophils.

Key words: interleukin-1ra, asthma, airway hyperresponsiveness, neutrophils

中图分类号:

R965.1
R976

陈雪芹, 曹霞, 杨炯, 曹作炎. 白细胞介素-1 受体拮抗剂与气道高反应性关系的研究[J]. 中国临床药理学与治疗学, 2004, 9(7): 759-762.

CHEN Xue-Qin, ZAO Xia, YANG Jiong, CAO Zuo-Yan. Research on relationship between interleukin-1 receptor antagonist and airway hyperresponsiveness[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(7): 759-762.

参考文献

1 Tillie-leblond I, Pugin J,Marqutte CH, Lamblin C, Saulnier F, Brichet A, et al.Balance between proinflammatory cytokines and their inhibit in bronchial lavage from patients with status asthmaticus[J].Am J Respir Crit Care Med, 1999;1599(2):487-94
2 Mao XQ, Kawai M, Yamashita T, Enomoto T, Dake Y, Sasaki S, et al.Imbalance production between interleukin-1 bata (IL-1bata) and IL-1 receptor antagonist(IL-1ra) in bronchial asthma [J].Biochem Biophys Res Commun, 2000;276(2):607-12
3 Tsukagoshi H, Sakamoto T, Xu W, Barnes PJ, Chung KF. Effect of IL-1β on airway hyperresponsiveness and inflammation in sensitized and nonsensitized Brown-Norway rats[J].J Allergy Clin Immuno, 1994;93(2):464-9
4 Barchasz E, Naline E, Molimard M, Moreaul J, Georges O, Emonds-Alt X, et al.Interleukin-1beta-induced hyperresponsiveness to substance P in isolated human bronchi[J].Eur J Pharmacol, 1999;379(2):87-95
5 王长征, 郭先健, 王顺朝.豚鼠哮喘模型的气道反应性测定[J].第三军医大学报, 1994;16:(1) 277-8
6 Dinarello C, Wolff SM.The role of interleukin-1 in disease[J]. N Engl J Med, 1993;328(2):106-13
7 Borish L, Mascali JJ, Dishuck J, Beam WR, Martin RJ, Rosennasser LJ, et al.Detection of alveolar macrophage-derived IL-1β in asthma:inhibition with corticosteroids[J].J Immunol, 1992;149(9):3078-82
8 Okada S, Inoue H, Asano M, Iijima H, Takishima T. Adjuvant effct of interleukin-1 on the development of late asthmatic response in guinea pigs[J].Int Arch Allergy Immunol, 1993;100(2):164-9
9 Stassen M, Amold M, Hulter L, Muller C, Neudorfl C, Reineke T, et al.Murine bone marrow-derived mast cells as potent producers of IL-9:costimulatory function of IL-10 and kit ligand in the presence of IL-1[J].J Immunol, 2000;164(11):5549-55
10 Diaz P, Gonzaloz MC, Galeguillos FR, Ancic P, Cromwell O,Shepherd D, et al.Leucocytes and mediators in bronchoalveolar lavage during allergen-induced latephase reacton[J].Am Rev Respir Dis, 1989;139(6):1383-9
11 Pauwels RA, Kips JC, Peleman RA, Van Der Straeten ME. The effect of endotoxin inhalation on airway responsiveness and cellular influx in rats[J].Am Rev Respir Dis, 1990;141(3): 540-6
12 Kelly C, Ward C, Stenton CS, Bird G, Hendrich DJ, Walters EH. Number and activity of inflammatory cells in bronchoalveolar lavage fluid in asthma and their relation to airway responsiveness[J].Thorax, 1988;43(9):684-9

[1]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[2]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[3]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[4]	赵子文, 范方田, 蒋志君. 诱导性支气管相关淋巴组织（iBALT）形成与相关肺疾病的研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 353-360.
[5]	林良沫, 符祥俊, 钟莉莉, 王和芳, 吴琼诗, 肖坚. 中性粒细胞缺乏患者万古霉素群体药代动力学模型的建立[J]. 中国临床药理学与治疗学, 2021, 26(9): 1014-1022.
[6]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[7]	易虹, 顾兵, 陈玉年, 李华南. 中性粒细胞胞外诱捕网及其在痛风性疾病中的作用[J]. 中国临床药理学与治疗学, 2021, 26(10): 1167-1173.
[8]	张磊. 基于网络药理学的郁金治疗哮喘的作用机制研究[J]. 中国临床药理学与治疗学, 2020, 25(1): 61-67.
[9]	王夏芹，何非，王同，胡章乐. 中性粒细胞/淋巴细胞比率对预测不稳定心绞痛患者冠脉病变严重程度和临床风险的意义[J]. 中国临床药理学与治疗学, 2019, 24(3): 296-300.
[10]	陈叶，贺守第，胡智立，冯斌. 香菇多糖对卵白蛋白诱导小鼠哮喘模型树突细胞TIM4表达及炎症影响[J]. 中国临床药理学与治疗学, 2018, 23(9): 998-1002.
[11]	吕平，彭万胜，董淮富. 新型抑制性细胞因子IL-35与支气管哮喘的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(2): 230-234.
[12]	余淑媛，郑麟，韩飞. 抗中性粒细胞胞质抗体相关性小血管炎的机制与治疗进展[J]. 中国临床药理学与治疗学, 2018, 23(2): 235-240.
[13]	张喜平，张翔，杨红健，邹德宏，乔恩奇，王准，何向明，俞星飞，章颖，唐镔镔. 多种复方中药注射液治疗小鼠化疗相关白细胞减少症[J]. 中国临床药理学与治疗学, 2018, 23(10): 1116-1125.
[14]	张佩红，陈啸洪，陈冰蓉，李华浚. 哮喘儿童血清细胞因子水平及布拉氏酵母菌干预的研究[J]. 中国临床药理学与治疗学, 2017, 22(3): 332-336.
[15]	滕承志，罗玲玲，张春丽. 沙丁胺醇与异丙托溴胺联合雾化对于小鼠哮喘炎症的影响及其网络药理学研究[J]. 中国临床药理学与治疗学, 2016, 21(8): 899-903.